Table 1.
Comparison of clinical and biochemical parameters for therapeutic efficacy evaluation pre and 8 weeks post Lu177-PSMA therapy by Wilcoxon signed-rank test
| Parameters | Pre therapy Mean ± SD |
Post therapy Mean ± SD |
P value |
|---|---|---|---|
| ECOG score (0–5) | 3.32 ± 0.57 | 3.05 ± 0.72 | 0.014 |
| VAS for pain (0–10) | 5.18 ± 2.15 | 3.63 ± 2.04 | < 0.000 |
| AQS (0–6) | 3.64 ± 0.49 | 2.91 ± 0.81 | 0.001 |
| PSA (ng/ml) | 143.32 ± 142.84 | 133.99 ± 159.21 | 0.115 |
Lu177-PSMA lutetium 177-prostate-specific membrane antigen, EGOG Eastern Cooperative Oncology Group, VAS visual analogue scale, AQS Analgesic Quantification scale, PSA prostate-specific antigen